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Purpose. To evaluate the potential of phosphate ester prodrugs to
significantly improve the absorptive flux of poorly soluble parent drugs.
Methods. Absorptive transport studies of parent drugs and their pro-
drugs were carried out in Caco-2 cells. Prodrugs of parent drugs with
variable aqueous solubilities were tested: Hydrocortisone-phosphate/
Hydrocortisone, Fosphenytoin/phenytoin, TAT-59/DP-TAT-59, and
Entacapone phosphate/Entacapone. Additional absorption studies
were carried out in rats.
Results. Absorptive fluxes of DP-TAT-59 and phenytoin increased
9.8 or 3.3-fold after dosing TAT-59 and 500 M fosphenytoin, re-
spectively. Hydrocortisone’s flux did not increase with hydrocorti-
sone-phosphate at 100 M. Permeability of the highly lipophilic and
protein bound compound, DP-TAT-59, was significantly increased
with serosal albumin. No permeability increase was observed for the
other drugs with albumin. Entacapone phosphate failed to improve
the flux of entacapone compared to an entacapone solution, but the
prodrug solution did yield higher entacapone plasma levels in rats
when compared with an entacapone suspension.
Conclusion. Ideal phosphate prodrug candidates are characterized by
high permeability and low solubility (BCS Class II drugs). For low
dose BCS Class II drug candidates, however, no biopharmaceutical
advantage may be gained. Phosphate prodrugs of parent drugs with
limited permeability may fail. When screening highly lipophilic par-
ent drugs transport studies should be done with albumin.
KEY WORDS: absorption; caco-2; permeability; phosphate ester
prodrug; protein effects.
INTRODUCTION
Phosphate prodrugs are often used to develop injectable
formulations of poorly soluble parent drugs and many are
marketed as injectable dosage forms (1). Following parenter-
al administration, the prodrugs are enzymatically cleaved by
endogenous alkaline phosphatases yielding the parent drug
(1,2). Examples for these “solubility-prodrugs” include Fos-
phenytoin (Cerebryx®, Pfizer) (3), for the treatment of status
epilepticus, prodrugs of glucocorticoids such as dexametha-
sone (Decadron-Phosphate®) (4), and Etoposide-phosphate
(Etopophos®, Bristol-Myers Squibb) for the treatment of
lung cancer (5).
However, very few oral phosphate prodrugs have made it
to the market place in spite of favorable dissolution charac-
teristics and their inherent chemical stability (6). Estramus-
tine phosphate (EMP), which is available in both intravenous
and oral formulations (7), has been on the market in Europe
and the United States as Emcyt® (Pharmacia) for the treat-
ment of prostate cancer. Prednisolone phosphate is available
as a liquid formulation (Pediapred®, Celltech). Monofluoro-
phosphate (Monocal®, Mericon) is not a ”solubility-prodrug”
but provides an oral dosage that shows less gastrointestinal
toxicity than sodium fluoride (8). An antiviral agent and pro-
drug of fludarabine, fludarabine phosphate (Fludara®, Ber-
lex, Schering) (9), was recently approved in Europe as an oral
dosage form and Fosamprenavir (VX-175/GW433908), a
phosphate ester prodrug of the HIV protease inhibitor am-
prenavir, is being developed by GlaxoSmithKline in an oral
dosage form to treat HIV infection in adults and children
(10).
Some oral prodrugs fail because of “lack of offering a
clinically relevant benefit” over the parent drug, such as oral
etoposide (11). Others fail because they do not improve rate
or extent of absorption of the parent drug in animal models,
such as LY307853 (12), or fail due to poor enzymatic biocon-
version, such as phosphate esters of taxol (13). The surprising
inability to use phosphate prodrugs by the oral route
prompted a study in a system being used to screen drug can-
didates for absorption potential. In Caco-2 intestinal absorp-
tion screening systems the drug flux (i.e., the amount of drug
passively absorbed per time per area (14)) is a product of drug
permeability and mucosal solution concentration. Since this
monolayer provides mucosal alkaline phosphatase activity
similar to that of normal human intestine, limited absorption
caused by low parent drug permeability can be clearly dem-
onstrated.
The purpose of this study is to determine whether phos-
phate prodrugs can significantly improve parent drug absorp-
tion flux across Caco-2 cell monolayers. The findings suggest
which drugs are the most ideal candidates for a phosphate
prodrug strategy. Phosphate prodrugs of parent drugs with
varying physico-chemical parameters were chosen for evalu-
ation in this study (Fig. 1). TAT-59 is an unusually lipophilic,
zwitterionic, phosphate prodrug of the extremely insoluble
DP-TAT-59 (BCS Class II) (15). Fosphenytoin is a conven-
tional dianionic prodrug of the poorly water-soluble phenyt-
oin (BCS Class II), a lipophilic compound with slow yet com-
plete absorption. Entacapone phosphate is a prodrug of the
weak acid entacapone, a hydrophilic parent drug with inter-
mediate solubility, which is soluble at intestinal pH, but is
insoluble at gastric pH (BCS Class IV). Hydrocortisone phos-
phate was chosen as a prodrug model compound with no
advantages from an oral delivery standpoint, since it is the
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prodrug of the soluble and permeable parent drug hydrocor-
tisone (BCS Class I, at low doses). In addition, since the
permeability of lipophilic parent drugs can be underestimated
in Caco-2 cells because of cell retention and non-specific
binding, the influence of basolaterally added albumin was
investigated (16). In vivo studies assessing absorption of the
triphenylethylene phosphate prodrug, TAT-59, were also
conducted in the rat intestinal perfusion model. Finally, the
utility of a phosphate ester prodrug strategy for entacapone to
increase that drugs systemic levels was evaluated in rats.
MATERIALS AND METHODS
Materials
TAT-59 and its parent drug, DP-TAT-59, were gifts of
Taiho Pharmaceutical Co., Ltd. (Tokushima, Japan). Entaca-
pone phosphate and its parent drug, entacapone, were gifts of
Orion Pharma (Turku, Finland). Fosphenytoin was donated
by Pfizer (formerly Parke-Davis, Ann Arbor, MI, USA). Hy-
drocortisone, hydrocortisone-phosphate, phenytoin and
tamoxifen were obtained from Sigma-Aldrich (St. Louis, MO,
USA).
3H-metoprolol (90 Ci/mmol) was obtained from
Moravek Biochemicals (Brea, CA, USA). 3H-tamoxifen (76
Ci/mmol), 14C-phenytoin (50 mCi/mmol), and 14C-mannitol
(51.5 mCi/mmol) were obtained from NEN Life Science
Products (Boston, MA, USA). Dulbecco’s modified Eagles
medium (DMEM, 4.5 g/L glucose) was purchased from
CELOX Laboratories (St. Paul, MN, USA). Fetal bovine se-
rum (FBS) was obtained from Atlanta Biologicals, Inc. (Nor-
cross, GA, USA). MEM nonessential amino acids (10 mM),
glutamine (200 mM), and Hank’s balanced salt solution
(HBSS) were purchased from Gibco BRL Life Technology
(Grand Island, NY, USA). Trypsin-versene mixture contain-
ing trypsin (0.5 mg/ml) and EDTA (0.2 mg/ml) was obtained
from BioWhittaker, Inc. (Walkersville, MD, USA). The
Caco-2 cell line was obtained from American Type Culture
Collection at passage 17 (Rockville, MD, USA). Other
chemicals were obtained from either Sigma-Aldrich or Gibco
BRL Life Technology.
Cell Culture
The Caco-2 cell model was chosen since they are derived
from human adenocarcinoma cells and form polarized mono-
layers that show alkaline phosphatase levels similar to levels
found in the human gut (17). Caco-2 cells were maintained in
T125 flasks and seeded at 70–80% confluency on 24-well Mul-
tiwell Plates®, BD BioSciences (Bedford, MA, USA) or Co-
star® 24-well plates (Cambridge, MA, USA) at the seeding
density of 75000 cells per 0.3 cm2 transwell. The cell plates
were maintained at 37°C with 5% CO2 and 95% humidity in
DMEM supplemented with 10% Fetal bovine serum, 1%
non-essential amino acids and 1% L-glutamine. Media was
changed every 48–56 h and cells used in this study were at
passages 22–49. Cell plates used were between 15 and 25 days
post seeding. Caco-2 monolayers formed under these condi-
tions typically yielded electrical resistance values of 600–1200
·cm2.
Caco-2 Transport Experiments
The apparent permeability of radiolabeled compounds
across Caco-2 cell monolayers was determined using 24-well
Caco-2 plates. In permeability experiments for all drugs ex-
cept TAT-59 and DP-TAT-59, HEPES-HBSS buffer (1.8 mM
CaCl2, 5.37 mM KCl, 0.44 mM KH2PO4, 0.49 mM MgCl2, 0.41
mM MgSO4, 136.89 mM NaCl, 4.17 mM NaHCO3, 3.38 mM
Na2HPO4, 5.55 mM D-glucose, and 5 mM HEPES, pH 7.4)
was used in both mucosal and serosal chambers. Due to TAT-
59’s limited solubility in the presence of free calcium, pH 7.4
HEPES buffer devoid of calcium was used on the apical side.
Since DP-TAT-59 is poorly soluble at pH 7.4, permeability
experiments were carried out at pH 6 using MES buffer (1.8
mM CaCl2, 5 mM KCl, 120 mM NaCl, 10 mM D-glucose, and
10 mM MES) and HEPES buffer (1.8 mM CaCl2, 5 mM KCl,
120 mM NaCl, 10 mM D-glucose, and 10 mM HEPES, pH
7.4) in the apical and basolateral sides, respectively. Prior to
experiments, culture medium was replaced with the respec-
tive buffers that had been warmed at 37°C, and the TEER
values were measured. The experiment was initiated by add-
ing 0.2 mL drug solution to the apical donor chamber and 1 ml
respective buffer to the receiver chamber. 14C-Mannitol (1.85
M) or 3H-metoprolol (4 nM) was used as cell monolayer
integrity and passive permeability markers, respectively.
Transport experiments were carried out at 37°C in either the
apical-to-basolateral (A-to-B) or the B-to-A direction (unless
otherwise stated). For DP-TAT-59 studies, ethanol or DMSO
Fig. 1. Structure of phosphate ester prodrugs. TAT-59 is provided as
the free acid, while the other prodrugs are disodium salts. In presence
of alkaline phosphatase the phosphate group is hydrolyzed to yield
the corresponding alcohol, or parent drug. Tamoxifen was used as a
reference compound.
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was used as a co-solvent at a final concentration of less then
2% (v/v). One hundred fifty microliter aliquots were sampled
and replenished from the receiver chambers at several time
points (30, 60, 90, or 120 min; or 0, 30, 60, 120, 150, 180 min).
Twenty microliter donor aliquots were minimally taken at 0
and 120 or 0 and 150 min. The radioactivity associated with
the samples was determined by scintillation counting using a
Packard Topcount counter.
The apparent permeability coefficient (Papp) of parent







where A is the surface area of the cell monolayer, CD(0) is the
initial concentration of parent drug in the donor chamber,
and dMR/dt is the linear appearance rate of parent drug mass
in the receiver chamber.
To compare parent drugs and prodrugs, the absorptive
(A-to-B) flux of the parent drug instead of Papp was calcu-
lated, since CD (0) for the permeable parent drug is not con-
stant during the experiment. Since no significant amount of
intact phosphate prodrugs can be detected in the basolateral
receiver chambers the transepithelial flux of parent drugs
(JA-B) expressed as nmol/cm
2/min, was calculated according






JA-B was determined as a function of the basolateral receiv-
er’s protein concentration ranging from 0 to 4% HSA at pH
7.4. Furthermore, the dosing concentration of parent drug
was varied by either dosing the parent drug directly or by
prodrug dosing. Cellular retention studies were carried out as
described by Aungst (16).
Rat Jejunal Perfusion Experiments of TAT-59, DP-TAT-59
and Hydrocortisone
Animal studies were carried our consistent with the
guidelines set by the National Institutes of Health (Publica-
tion 85-23, revised 1985). The perfusion studies were carried
out as previously reported (18,19) in fasted male Sprague-
Dawley rats weighing approximately 300–400 g. Propranolol
was added to drug solutions as a high permeability marker.
Relative prodrug loss from the perfusate was measured by a
reverse phase HPLC assay that utilizes an ion-pairing reagent
that allowed detection of both parent and prodrug. The ef-
fective permeability (Peff) measured by intestinal perfusion
was based on the loss of drug from the perfusate
Peff = − Q2rLlnCoutCin 
where Q is the perfusate flow rate through the segment (0.14
ml/min), r is the radius of the segment (0.2 cm), L is the length
of the perfused segment (10 cm), and Cin is the drug or pro-
drug concentration of the perfusate entering the intestinal
segment. Cout is the remaining prodrug and parent drug con-
centration in the exiting perfusate, (Cout), corrected for water
transport by using the gravimetry method.
Entacapone and Entacapone Phosphate Pharmacokinetics
in Rats
Male Han/Wistar rats (National Laboratory Animal
Center, Kuopio, Finland), weighing 180–300 g (n  44) were
fasted 24 h before the experiment. Tap water was available ad
libitum. Animals were decapitated 0, 0.5, 1, 2, 4 or 6 h after
oral administration of 1.867 × 10−5mol/kg entacapone parent
drug (equivalent to 5.7 mg/kg) as a clear solution (pH 7.4) or
as its phosphate prodrug solution (pH 7.4). All procedures
with animals were reviewed and approved by the Animal
Ethics Committee at the University of Kuopio.
Blood was collected into tubes containing disodium-
EDTA. Plasma was separated by centrifugation for 10 min at
1500 g at +4°C and samples were stored at −70°C until ana-
lyzed. Plasma entacapone concentrations were determined
according to Savolainen et al. (20). Area under concentration-
time curve values (ng/ml × h) from 0 to 2 h and from 0 to 6 h
were calculated by Graph Pad Prism 3.02 software (Graph
Pad Software, San Diego, California, USA) using the trap-
ezoid rule. The relative bioavailabilities (Frel) of entacapone
phosphate (pH 7.4) and entacapone suspension (pH 3.0) were
calculated by equation
Frel = AUCAAUCBDoseBDoseA
where A refers to entacapone phosphate solution or entaca-
pone suspension and B to entacapone solution. The AUC0-2
h value of entacapone suspension was calculated from earlier
published data (20). In the case of entacapone phosphate,
only plasma entacapone concentrations were used for calcu-
lations (intact entacapone phosphate was detected only in
three samples).
RESULTS
TAT-59 and DP-TAT-59 Transport across Caco-2
Cell Monolayers
The flux of DP-TAT-59 was found to be dependent on
basolateral protein concentration as well as on parent and
prodrug dosing concentrations. At 20 M concentration of
DP-TAT-59, the Papp was below that of the non-permeable
marker mannitol in the absence of albumin [0.096 (± 0.03) ×
10−6 cm/s], while this triphenylethylene derivative showed a
higher permeability than the high permeability marker met-
oprolol in the presence of 4% albumin [32.6 (± 6.5) × 10−6
cm/s] (Table I). Papp also increased in the presence of lower
levels of albumin and was 2.6 (±0.7) × 10−6 cm/s and 14 (±2.6)
× 10−6 cm/s, in presence of 0.5% and 1% HSA, respectively.
The absorptive flux of DP-TAT-59 is lower than that of TAT-
59 at equimolar dosing of prodrug and parent drug (Fig. 2A).
At 100 M, dosing TAT-59 increased the absorptive flux of
DP-TAT-59 [9.09 (±3.9) nM/cm2/min] by nearly 10-fold,
which is characteristic of the increased solubility achieved by
the prodrug approach [89.39 (± 36.4) nM/cm2/min] (Table II).
On the contrary, at 10 M dosing, no pronounced difference
in flux was observed. The likely reason for this observation is
that poor aqueous solubility of DP-TAT-59 limits its absorp-
tive flux. DP-TAT-59 is extremely insoluble in pH 7.4 buffer
(0.1M) and is still insoluble even at pH 6.0 (9.3 M) (15).
Thus, when DP-TAT-59 is dosed as a suspension at 100 M,
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its solution concentration is still limited by its solubility near
10 M, and therefore the observed flux remains low. The
prodrug TAT-59 however, is soluble up to 100 M when
dosed at pH 7.4, which on apical dephosphorylation may yield
supersaturated DP-TAT-59 solutions and supersaturation ra-
tios near 60 have been observed (15).
Polarized permeation of TAT-59 across Caco-2 cell
monolayers was observed at 100 M concentration with a
JA-B of 89.39 ± 36.4 compared to JB-A 8.18 ± 0.92 nmole/cm
2/
min (Table II). This 11-fold higher A-to-B permeability of
TAT-59 suggests that the prodrug is rapidly dephosphory-
lated by apical alkaline phosphatase to yield the non-charged
DP-TAT-59, which is then absorbed. The unexpected, high
JB-A flux after basolateral prodrug dosing is apparently the
result of TAT-59’s physicochemical properties. TAT-59 is an
unusually lipophilic phosphate ester, and its anionic charge is
masked, since it possesses a basic alkylamimo side chain. At
intestinal pH, TAT-59 can exist up to nearly 50% as a neutral
zwitterion with the remaining fraction being the net-
monoanion. Even though the net-monoanionic form pre-
dominates at basolateral pH, the prodrug exists in significant
amounts as a zwitterion. The zwitterionic TAT-59 is respon-
sible for the unusually high log D when compared to other
phosphates, of 1.2 at pH 6.5 and 0.08 at pH 7.4 (Table III),
respectively (15). For DP-TAT-59 a smaller asymmetry with
JB-A/JA-B near 3.0 and 4.3 was observed for 10 M and 100
M, respectively (Table II). This effect can be explained by
the pH asymmetry often observed with weak bases when the
apical pH used in the transport studies is lower than that of
the basolateral pH (21) or by involvement of an efflux system.
Entacapone Phosphate and Entacapone Flux across Caco-2
Cell Monolayers
Entacapone was found to be poorly absorbed in Caco-2
cells [1.1 (± 0.3) × 10−6 cm/s] and its Papp was not increased in
the presence of basolateral albumin (Table I). Furthermore,
the prodrug of entacapone did not improve the absorptive
flux over that of entacapone, which was low compared to
those of the other parent drugs such as hydrocortisone (Fig.
2B).
Hydrocortisone Phosphate and Hydrocortisone Flux across
Caco-2 Cell Monolayers
No significant differences in hydrocortisone flux were
seen for hydrocortisone-phosphate and hydrocortisone when
the compounds were dosed below the solubility of the parent
Table I. Effect of Protein Added to Basolateral Receiver Chambers










DP-TAT-59a 0.00005 0.096 ± 0.03b 32.6 ± 6.5b
Phenytoin 0.02 33.49 ± 1.18 29.9 ± 2.92
Entacapone 1.75 1.1 ± 0.05 0.32 ± 0.5c
Hydrocortisone 0.28 17.49 ± 4.13 16.7 ± 1.2
LY303366 0.005 3.5 ± 1.10d NA
Metoprolol (Reference) NA 22.9 ± 2.75 20.6 ± 3.8
Mannitol (Reference) NA 1.1 ± 0.3 0.9 ± 0.26
Note: Data are presented as the mean ± SD. of 3–6 determinations.
CS: Minimal aqueous solubility at neutral pH from references
(3,15,29). NA: not available, compounds are freely soluble.
a This experiment was performed at pH 6.0 and 7.4 in the apical
donor and basolateral receiver chambers, respectively.
b Significantly different from the respective control (p < 0.001).
c 1% HSA.
d From Li et al. (37).
Fig. 2. Absorptive fluxes of parent drugs across Caco-2 cells mea-
sured after dosing parent drugs and their corresponding phosphate
prodrugs. The A-to-B parent drug fluxes were determined as a func-
tion of basolateral human serum albumin [HSA] concentration and
drug concentration. (A) Parent Drug DP-TAT-59, dosed as a suspen-
sion, and Prodrug TAT-59; (B) Parent drugs Entacapone [E] and
Hydrocortisone [H], and their corresponding prodrugs, Entacapone
phosphate [EP], Hydrocortisone-Phosphate [HP], respectively; (C)
Parent drug phenytoin [DPH] and prodrug fosphenytoin [FDPH].
Each point represents the mean (± SD.) of 3–8 determinations.
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drug (near 100 M) and absorptive fluxes were consistent
with high intestinal permeability (Fig. 2B). An increase in
membrane permeability with the phosphate prodrug had
been previously reported in rat jejunum and while a higher
Cmax and earlier tmax was observed with oral administration
of the prodrug in dogs, oral bioavailability was lower with the
prodrug as compared to the parent steroid (22).
Fosphenytoin and Phenytoin Fluxes across Caco-2
Cell Monolayers
Phenytoin’s flux increased 2.7-fold to 3.3-fold after high
dosing concentrations of fosphenytoin of 300 and 500 M,
respectively (Fig. 2C). The parent drug is regenerated rapidly,
yet variably in apical donor cells, with an apparent half-life
t1/2of 27.7 ± 13.8 min. (data not shown) suggesting that de-
phosphorylation is complete within typical human small in-
testinal residence times of 3–4 h. No precipitation or turbidity
of donor solutions was observed during the duration of trans-
port experiments.
TAT-59 and DP-TAT-59 Rat Jejunal Permeability
In the rat model DP-TAT-59 is well absorbed after jeju-
nal dosing of TAT-59 and DP-TAT-59, compared to high
permeability markers hydrocortisone and propranolol (Fig.
3). The results are in agreement with previous work (23).
After prodrug dosing, the dephosphorylation is catalyzed by
alkaline phosphatase and DP-TAT-59 is reportedly absorbed
(23). However, after 100 M dosing of TAT-59 the Peff is not
significantly reduced in the presence of L-phenylalanine (L-
Phe) an alkaline phosphatase inhibitor, suggesting possible
absorption of TAT-59 or inefficient inhibition.
Entacapone and Entacapone Phosphate Pharmacokinetics
in Rats
Plasma entacapone levels were slightly lower after oral
administration of entacapone phosphate solution (pH 7.4)
than after entacapone solution (pH 7.4) but higher than after
entacapone suspension (pH 3.0), as is shown in Fig. 4. The
AUC
0-2 h
values of entacapone after administration of entaca-
pone solution, entacapone phosphate solution and entaca-
pone suspension were 1728, 1149, and 475 ng/ml × h, respec-
tively. Correspondingly, the plasma entacapone concentra-
tions at 0.5 h after dosing were 2017 ± 207, 1111 ± 298, and 500
± 75 ng/ml (mean ± SEM; n  4 × 15). The AUC0-6 h values
of entacapone solution and entacapone phosphate were 2616
ng/ml × h and 1586 ng/ml × h, respectively. The relative bio-
availabilities of entacapone phosphate and entacapone sus-
pension were 66% and 28% (entacapone solution as refer-
ence dosage).
Effect of Lipophilicity and Protein Binding on the
Apparent Permeability of Parent Drugs in Caco-2 Cells
The drug flux or permeability of lipophilic compounds
can be underestimated in Caco-2 cells for highly lipophilic or
protein bound compounds due to cellular retention or non-
specific binding (16,24). This has been previously demon-
strated for tamoxifen which is in the same chemical and thera-
peutic class as TAT-59. Papp (A-B) of highly lipophilic and
protein bound compounds, DP-TAT-59, TAT-59 and tamoxi-
fen were significantly increased in the presence of basolateral
albumin (Table I). This was not the case for hydrocortisone,
phenytoin, and entacapone which are less lipophilic and not
as highly protein bound compared to TAT-59 (Tables I, III).
Furthermore, 4% albumin significantly increased the release
of DP-TAT-59 and tamoxifen from Caco-2 cells, compared to
control, but this effect was not observed for hydrocortisone
and phenytoin (Fig. 5).
DISCUSSION
A phosphate prodrug approach offers several advantages
when developing or formulating a poorly soluble compound
for which conventional formulation approaches, such as salt
selection, particle size reduction and use of solubilizing agents
have failed or are impractical. Phosphate prodrugs are chemi-
cally stable, their synthesis is usually straightforward in the
presence of a hydroxyl moiety (6) and the increase in solu-
bility imparted by the dianionic phosphate group is often 2–3
orders in magnitude (3). Less use of solubilizing excipients
can lead to cost reduction and a higher drug load in capsules
(10), allowing for a more convenient dosage regimen. Despite
these advantages very few phosphate prodrugs are developed
beyond the discovery stage.
Failure of phosphate prodrugs to increase drug absorp-
tion can be attributed to several potential rate-limiting factors
in the drug absorption process (25). After oral administration,
phosphate ester prodrugs are dephosphorylated in the GI
tract by membrane-bound alkaline phosphatase (AP). In
theory, the lipophilic parent drugs generated are well ab-
sorbed compared to the polar prodrugs and drug flux is in-
creased. The maximum flux, or amount of parent drug pas-
sively absorbed per time per area (14), can be expressed as:
J = Peff Cs
where J is the absorption flux, Peff is the effective permeabil-
ity, and Cs is the mucosal parent drug concentration which is
maximum at the drug’s solubility. Maximum driving force







TAT-59 (10 M) 12.3 ± 8.79 5.15 ± 3.64
DP-TAT-59 (10 M)b 7.94 ± 3.45 23.55 ± 5.7d
TAT-59 (100 M)c 89.39 ± 36.4d 8.18 ± 0.92
DP-TAT-59 (100 M)b 9.09 ± 3.9 39.09 ± 16.36d
a This experiment was performed at pH 7.4 in both the apical and
basolateral chambers for TAT-59 due to the prodrug’s low solubility
at pH 6.5. For DP-TAT-59, apical donor solutions with pH 6.0 were
employed, due to DP-TAT-59’s low solubility at pH 7.4 in absence
of HSA. Basolateral DP-TAT-59 solutions were at pH 7.4 and con-
tained 4% HSA. Data are presented as the mean ± S.D. of 3–6
determinations with Caco-2 monolayers.
b Concentrations are not solution concentrations but are those of the
dosed suspensions due to the very low solubility of DP-TAT-59 at
neutral pH.
c The flux is determined by the appearance of the permeable parent
drug, DP-TAT-59 on the receiver side; TAT-59 concentration in
receiver side is negligible.
d Significantly different from the respective parent control and B-A
control (p < 0.01).
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requires a sink condition assumption that is not unreasonable
for most drugs given the small amount of drug entering the
basolateral compartment in the Caco-2 system. For drugs, like
DP-TAT-59, for which cellular accumulation may diminish
the transepithelial driving force, basolateral albumin serves to
maintain sink conditions in line with in vivo absorption.
Phosphate ester prodrugs often exhibit an aqueous solu-
bility that is several orders higher than that of the correspond-
ing parent drug compounds (1,15). Following enzymatic con-
version of the prodrug solution, parent drug solution concen-
tration above the parent drug’s equilibrium solubility may be
achieved leading to parent drug supersaturation, or the par-
ent drug may be solubilized in the presence of the dianionic
prodrug (15) increasing the driving force for absorption.
Thus, the transepithelial concentration gradient Cs, driving
drug flux, can be enhanced if Peff is not rate limiting to ab-
sorption.
If the prodrug hydrolysis rate is first order, the surface
reaction kinetics can be lumped into the effective permeabil-
ity that takes the form of a hyperbolic trigonometric function
of hydrolysis and membrane permeation parameters (26).
Further, enzymatic prodrug hydrolysis may follow Michaelis-
Menten kinetics as a function of prodrug concentration. If
enzymatic hydrolysis controls permeation rate, enzyme ki-
netic parameters can be used as a transport membrane
boundary condition similar to membrane permeation that is
subject to carrier-mediated saturation (27).
Potential rate limits to parent drug absorption from
phosphate prodrugs thus include prodrug dissolution and po-
tential parent drug precipitation, enzymatic bioconversion to
the parent drug by membrane-bound alkaline phosphatase
(28) and limited intestinal permeability of the parent drug.
This study indicates that intestinal permeability of parent
drugs can limit the success of a phosphate prodrug strategy.
While other rate limitations are possible, phosphate esters
usually increase solubility and dissolution rates and alkaline
phosphatase is a non-specific enzyme that efficiently cleaves a
wide range of esters including thioesters (28). This is illus-
Fig. 3. DP-TAT-59 and TAT-59’s Intestinal Permeability in the Rat
Jejunum. The effective permeabilities Peff of Parent Drugs deter-
mined in phosphate buffer in the rat intestinal perfusion model. The
calculated Peff after prodrug dosing is based on the loss of parent
drug. Results represent mean ± SEM from at least 4 animals.
Fig. 4. Entacapone plasma levels in rats after oral administration.
() Entacapone dosed as a solution at pH 7.4; () Entacapone dosed
as its prodrug, entacapone-phosphate, in solution at pH 7.4; and ()
Entacapone dosed as a suspension at pH 3. Entacapone dose was
kept constant at 1.867 × 10−5 mol/kg. Each data point represents the
mean ± SEM of 4-15 determinations. Entacapone suspension data is
from Savolainen et al. (20).
Table III. Albumin Effect on the A-B Permeability of Drugs across Caco-2 Cells
a
Parent or prodrug
HSA effect on A-B Papp






Tamoxifen (Reference) 22.3-fold 5.7e >98 NAh
DP-TAT-59 >25-fold >3.0 (pH 6.5) >99.9 NAh
0.08 (pH 7.4) 28.8 (rats)
TAT-59f >25-fold 1.2 (pH 6.5) >99.9 23.8 (dogs)
Hydrocortisone not significant 1.6 75–95, 89 96 (human)
Phenytoin not significant 2.5 89 90 (human)
Entacaponeg not significant 0.18 98 29–46
Metoprolol (Marker) not significant 1.97 10 38
Mannitol (Marker) not significant −3.1 10 NAh
a Experiments were done with 4% HSA.
b Distribution coefficient in octanol/water.
c,d Data were compiled from the literature (15,16).
e Calculated using ACD Lab.
f Papp is based on parent drug, since prodrug is not detected in basolateral receivers.
g 1% HSA.
h NA: no literature bioavailability data available.
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trated utilizing several phosphate ester prodrugs with varying
physico-chemical properties and targeted doses, namely hy-
drocortisone-phosphate, fosphenytoin, TAT-59, and entaca-
pone phosphate. While these prodrugs are rapidly dephos-
phorylated in the presence of alkaline phosphatase (15,23,29)
their parent drugs differ in their degree of permeability-
lipophilicity.
Hydrocortisone-phosphate (Hydrocortone-Phosphate®,
Merck) is only available as the prodrug for parenteral use,
while for oral administration the parent drug is marketed.
Hydrocortisone for oral delivery (Hydrocortone®, Merck) is
a low dose compound (5–20 mg) and this polar steroid has a
relatively high solubility near 0.3 mg/ml at intestinal pH (15).
Combined with its high Peff in rats (22) (Fig. 3) and its bio-
availability of 96% it can be concluded that hydrocortisone is
completely absorbed at the low doses typically administered.
While a prodrug would likely be bioequivalent as is the case
with the steroid drug prednisolone (30), the hydrocortisone-
phosphate prodrug would not offer any biopharmaceutical
advantage for drug delivery at usual oral doses. In our Caco-2
experiments hydrocortisone and hydrocortisone-phosphate
both were both well absorbed and had similar high absorptive
fluxes (Fig. 2B). In the case of this highly soluble parent drug,
the prodrug approach did not significantly increase the parent
drug flux. The success of a phosphate prodrug for a parent
drug with sufficient solubility to completely dissolve within
small intestinal residence time should be a function of the
targeted dose. In the case of glucocorticoids, it is possible that
a phosphate prodrug would improve absorption at some of
the very high oral doses used in chemotherapy.
Fosphenytoin is a successful parenteral prodrug of phe-
nytoin (Dilantin®), which exhibits a high aqueous solubility
of 140 mg/ml compared to the 20 g/ml of the practically
insoluble phenytoin (3). Phenytoin is a BCS Class II drug (i.e.,
a drug with low solubility and high permeability) (14). Its
absorption is nearly complete in humans when dosed as its
soluble sodium salt, but erratic at doses of 100 mg (31). For
that reason the prodrug would only offer a flux advantage in
humans if high doses of phenytoin were to be administered.
At high doses phenytoin’s absorption will be solubility-
dissolution rate limited. With the prodrug fosphenytoin, so-
lution concentrations of phenytoin above its equilibrium solu-
bility can be achieved without precipitation, likely due to su-
persaturation. Thus, fosphenytoin and phenytoin represent a
case where the flux can be increased for poorly to moderately
soluble parent drugs when high doses are required. In fact,
oral dosing of fosphenytoin has been found to yield an earlier
tmax and higher Cmax in rats (32) and dogs (3) and has also
lead to an increased relative bioavailability in that species (3).
TAT-59 (Miproxifene Phosphate) was under develop-
ment and in clinical trials by Taiho Pharmaceutical Co. Ltd.
for the treatment of breast cancer (33), with a recommended
dose of 20 mg. TAT-59 is a practical insoluble phosphate ester
(34) of DP-TAT-59 (Fig. 1). The prodrug approach had been
chosen, since unlike tamoxifen, no stable citrate or other salt
of DP-TAT-59 could be synthesized. Despite TAT-59’s low
solubility in water (34), its solubility is higher than that of
DP-TAT-59. TAT-59 through its metabolite DP-TAT-59 was
previously shown to be well absorbed in rats (23), yet in the
Caco-2 model the measured permeability of DP-TAT-59 was
low when no albumin was added [0.096 (± 0.3) × 10−6 cm/s].
The permeability was significantly increased in the presence
of albumin [32.6 (± 6.5) × 10−6 cm/s] (Table I), implying high
intestinal permeability in vivo. Due to its low solubility and
high permeability, DP-TAT-59 is a BCS Class II drug. TAT-
59 is a successful phosphate prodrug since it increased drug
flux of DP-TAT-59 by nearly 10-fold (Table II) at a concen-
tration relevant for human dosing. This lipophilic parent drug
is an example where the prodrug approach can increase the
parent drug flux through an increase in aqueous solubility,
since the low solubility of the parent drug is a rate-limiting
step for absorption.
Entacapone phosphate is an investigative phosphate es-
ter prodrug of entacapone (Comtan®). Entacapone is rapidly
absorbed but has a low and variable bioavailability of 29–46%
in humans (35). One of the reasons for the low bioavailability
was thought to be entacapone’s pH dependent solubility,
which is that of a typical weak acid (20,36). At pH 1.2, enta-
capone’s solubility is near to 0.017 mg/ml, but it rises to 1.75
mg/ml at pH 7.4 (20,29). The rationale for synthesizing a
phosphate prodrug of entacapone was to increase the aque-
ous solubility and dissolution rate of entacapone (29) since
the improved solubility could lead to higher plasma entaca-
pone levels and improved bioavailability. The aqueous solu-
bility of entacapone phosphate was found to be significantly
higher than that of entacapone, both at pH 1.2 and 7.4 (29).
Present results also suggest that bioavailability of entacapone
can be improved with the prodrug. The AUC0-2 h of entaca-
pone was higher after administration of entacapone phos-
phate than after administration of entacapone suspension and
the relative bioavailability of entacapone phosphate was over
2-fold better than that of entacapone suspension. Thus, be-
cause of its increased solubility, the phosphate prodrug seems
to overcome the dissolution problem related to the poor bio-
availability of parent entacapone. In this study, the adminis-
tration of a solid dosage form was simulated by giving enta-
capone as a suspension. However, the prodrug did not yield
plasma levels as high as those achieved with entacapone so-
lution. The fact that entacapone flux was not significantly
increased in Caco-2 cells (Fig. 2B), is not surprising since the
parent drug has moderate solubility and its absorption is
likely permeability rate-limited. Since the plasma entacapone
Fig. 5. Release Profiles of Drugs from Caco-2 Cell Monolayers. The
release of Tamoxifen () and DP-TAT-59 () from 24-well Caco-2
monolayers significantly increased (p < 0.01) in the presence of 4%
HSA compared to pure buffer lacking HSA (). No significant in-
crease compared to a control was observed for hydrocortisone ()
and phenytoin (). Each data point represents the mean ± SD of 4
determinations.
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levels and the relative bioavailability were lower after dosing
entacapone as a phosphate prodrug solution than as the par-
ent-drug solution, the phosphate pro-moiety may hinder ab-
sorption of entacapone, or its enzymatic hydrolysis may be-
come rate limiting.
Another example where drug permeability limits a pro-
drug approach to improve absorption is the echinocandin B
analog LY303366. LY303366 has a poor intestinal permeabil-
ity, as measured in the Caco-2 model (37) (Table I), in spite
of a favorable log octanol/water partition coefficient of 2.0.
Limited solubility of 0.005 mg/ml led to the development of
the phosphate prodrug, LY307853. While the prodrug greatly
increased aqueous solubility, it failed to improve LY303366
plasma levels in dogs (12). In contrast, an example of a phos-
phate prodrug with good parent drug permeability is the re-
cently approved oral dosage form of fludarabine-phosphate
(Fludara®, Schering) (9), where the IV formulation was mar-
keted first.
For all phosphate esters studied, no significant amount of
intact prodrug was detected in receiver chambers. Apical pro-
drug and parent drug concentrations are time dependent, as
was shown for fosphenytoin and phenytoin, suggesting rapid
dephosphorylation by apical alkaline phosphatase followed
by absorption of the permeable parent drug, while the highly
charged phosphate is not absorbed in significant amounts. For
that reason, the success of a phosphate prodrug strategy is
dependent on the permeability of the parent drug.
Moreover, the drug flux or permeability of lipophilic or
highly plasma bound compounds, which are ideal phosphate
prodrug candidates can be underestimated in the Caco-2
model (24). For phenytoin and tamoxifen the results are con-
sistent with a previous study that showed a 1.4-fold increase
for phenytoin, while tamoxifen could not be detected in the
absence of albumin and Papp could not be determined (16).
The use of albumin in Caco-2 transport studies apparently
reduces intracellular accumulation of highly protein bound
drugs and mimics more physiologic sink conditions, as the
albumin concentration in vivo is near 4% (16). To avoid an
underprediction of absorption following both parent and pro-
drug dosing, it is therefore suggested to add albumin to the
basolateral chambers.
In conclusion, this study demonstrated that, when target-
ing phosphate prodrugs for oral delivery, the permeability of
the parent drugs could rate limit the absorptive flux. For that
reason ideal phosphate prodrug candidates have a high per-
meability or lipophilicity and low solubility (i.e., are BCS
Class II drugs, such as DP-TAT-59). However, for BCS Class
II drugs administered at sufficiently low doses to permit com-
plete dissolution within intestinal residence time, such as hy-
drocortisone and phenytoin, no biopharmaceutical advantage
is gained. Phosphate prodrugs are not likely to optimize the
absorptive drug flux of parent drugs with low permeability
and intermediate to high solubility, such as entacapone. Fur-
thermore, when using the Caco-2 model to evaluate phos-
phate ester prodrugs, albumin should be added to basolateral
receivers for highly lipophilic parent drugs, since failure to
consider protein binding can result in the underestimation of
absorption.
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